中文

赛托生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.33B+26.2%
Gross profit¥0.07B
Operating income¥0.01B
Net income¥0.00B
Gross margin22.1%Net margin 1.4%
Revenue Q/Q+22.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.26B77.9%
R&D¥0.01B3.1%
SG&A¥0.04B12.0%
Tax & other¥0.00B0.3%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

海辰药业奥联电子美联新材天铁科技熙菱信息江龙船艇移为通信万里马华凯易佰新雷能ST朗进欧普康视

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies